Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Malignant pheochromocytoma.

Rasa Zarnegar1, Electron Kebebew, Quan-Yang Duh

  • 1Department of Surgery, University California San Francisco, Comprehensive Cancer Center at Mount Zion, Medical Center, 1600 Divisadero Street, Hellman Building, Room C347, San Francisco, CA 94143-1764, USA. Zarnegar.rasa@gmail.com

Surgical Oncology Clinics of North America
|August 3, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

CRISPR-Based Gene Dependency Screens Reveal Mechanism of BRAF Inhibitor Resistance in Anaplastic Thyroid Cancer.

Molecular carcinogenesis·2026
Same author

Workforce growth without reach: National trends in access to high-volume parathyroid surgeons.

Surgery·2026
Same author

Succinate dehydrogenase-deficient cancer cells have increased susceptibility to Ym155-induced DNA damage.

Endocrine-related cancer·2026
Same author

Utilization of thyroid ultrasound and surgery after glucagon-like peptide-1 receptor agonist prescription.

Surgery·2026
Same author

Dual targeting of BRAF<sup>V600E</sup> and ferroptosis results in synergistic anticancer activity via iron overload and enhanced oxidative stress.

Journal of experimental & clinical cancer research : CR·2026
Same author

Corrigendum to "Combination nitazoxanide and auranofin treatment has synergistic anticancer activity in anaplastic thyroid cancer through enhanced activation of oxidative stress that leads to apoptosis" [Cancer Letters 633 (2025) 217990].

Cancer letters·2025
Same journal

Small Incisions, Big Impact-Robotic Surgery Is Revolutionizing Cancer Care.

Surgical oncology clinics of North America·2026
Same journal

Minimally Invasive and Robotic Surgery for Cancer.

Surgical oncology clinics of North America·2026
Same journal

TeleSurgery: The Present and the Future for Minimally Invasive and Robotic Surgery.

Surgical oncology clinics of North America·2026
Same journal

Minimally Invasive and Robotic Surgery for Rectal Cancer.

Surgical oncology clinics of North America·2026
Same journal

Minimally Invasive/Robotic Surgery for Colon Cancer.

Surgical oncology clinics of North America·2026
Same journal

Minimally Invasive Surgery in Liver Transplantation.

Surgical oncology clinics of North America·2026
See all related articles

Malignant pheochromocytoma, a rare and deadly cancer, is difficult to diagnose preoperatively. Identifying molecular markers could improve surgical treatment and follow-up for this challenging endocrine tumor.

Area of Science:

  • Endocrinology
  • Surgical Oncology
  • Oncology

Background:

  • Malignant pheochromocytoma is a rare endocrine neoplasm associated with high mortality.
  • Current diagnostic methods cannot reliably distinguish between benign and malignant pheochromocytoma without evidence of metastasis.
  • This diagnostic uncertainty can lead to delayed detection and treatment of recurrent disease.

Purpose of the Study:

  • To highlight the diagnostic challenges in differentiating benign from malignant pheochromocytoma.
  • To emphasize the need for improved diagnostic strategies, including molecular markers.
  • To discuss the implications for surgical treatment and follow-up protocols.

Main Methods:

  • Review of current literature on pheochromocytoma diagnosis and management.

Related Experiment Videos

  • Analysis of the limitations of existing diagnostic criteria.
  • Exploration of emerging molecular markers for malignancy.

    • Main Results:

    • Preoperative differentiation between benign and malignant pheochromocytoma remains a significant clinical challenge.
    • The absence of definitive markers often results in delayed diagnosis of recurrence.
    • Emerging molecular markers show promise for improved diagnostic accuracy.

    Conclusions:

    • Accurate preoperative diagnosis of malignant pheochromocytoma is crucial for appropriate surgical planning and patient management.
    • Further research into molecular markers is essential for establishing definitive diagnostic criteria.
    • Improved diagnostic capabilities will enable tailored surgical approaches and follow-up strategies, potentially improving patient outcomes.